Fatty liver disease promotes the formation of kidney stones

Aug 25, 2021

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in western countries, with an increasing incidence worldwide. Consequences of NAFLD can also include kidney disease and kidney stones, although the mechanisms for the development of these kidney complications as a result of NAFLD have not yet been fully explained. Researchers at the Leibniz Research Centre for Working Environment and Human Factors in Dortmund (IfADo) have now published a paper on how fatty liver disease promotes the formation of kidney stones.

Researchers at the IfADo have found out in studies that the metabolic processes in the liver are disturbed by fatty liver disease. As a result, there is a higher accumulation of oxalate. Oxalate is not only present in some foods, but is formed as a metabolic product in the liver and excreted through the kidneys in the urine. An increased concentration of oxalate in the urine is associated with a higher risk of progression of chronic kidney disease because oxalate binds calcium, which can lead to the formation of kidney stones.

Although kidney stones are usually not life-threatening, they often recur and are the cause of chronic kidney disease. In a healthy liver, the enzyme Alanine Glyoxylate Aminotransferase (AGXT) prevents excessive formation of oxalate. However, the IfADo study shows that AGXT expression is decreased in fatty liver and therefore cannot fulfill its function sufficiently. Fatty liver disease is thus also a risk factor for kidney stones and chronic kidney disease.

Original publication:
Kathrin Gianmoena, Nina Gasparoni,  Adelina Jashari, Philipp Gabrys, Katharina Grgas, Ahmed Ghallab, Karl Nordström, Gilles Gasparoni, Jörg Reinders, Karolina Edlund, Patricio Godoy, Alexander Schriewer, Heiko Hayen, Christian A. Hudert, Georg Damm, Daniel Seehofer, Thomas S. Weiss, Peter Boor, Hans-Joachim Anders, Manga Motrapu, Peter Jansen, Tobias S. Schiergens, Maren Falk-Paulsen, Philip Rosenstiel, Clivia Lisowski, Eduardo Salido, Rosemarie Marchan, Jörn Walter, Jan G. Hengstler, Cristina Cadenas: Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluri, Cell Reports, VOLUME 36, ISSUE 8, 109526, AUGUST 24, 2021. DOI: https://doi.org/10.1016/j.celrep.2021.109526

Scientific Contact:
Dr. rer. nat. Cristina Cadenas
Head of Group Interorgan Toxicology

Phone: +49 231 1084-392
Email: cadenas@ifado.de

Press Contact:
Anne Rommel
Press Officer
Phone: +49 231 1084-239
Email: rommel@ifado.de